Brief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Nov 18 (Reuters) - Lytix Biopharma AS LYTIX.OL: Q3 LOSS FOR PERIOD NOK 23.3 MILLION VERSUS LOSS NOK 22.7 MILLION YEAR AGO Source text: ID:nWkr98LlK6 Further company coverage: LYTIX.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lytix Biopharma AS
See all newsBrief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program